160 related articles for article (PubMed ID: 29721370)
1. A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Choi JH; Kim KH; Roh KH; Jung H; Lee A; Lee JY; Song JY; Park SJ; Kim I; Lee WS; Seo SK; Choi IW; Fu YX; Yea SS; Park S
Oncoimmunology; 2018; 7(5):e1421890. PubMed ID: 29721370
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.
Song H; Kim TO; Ma SY; Park JH; Choi JH; Kim JH; Kang MS; Bae SK; Kim KH; Kim TH; Seo SK; Choi IW; Song GA; Mortenson ED; Fu YX; Park S
BMC Cancer; 2014 Sep; 14():647. PubMed ID: 25179116
[TBL] [Abstract][Full Text] [Related]
3. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
4. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
5. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
6. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
7. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
Kim HY; Choi JH; Haque MM; Park JH; Kim IH; Choi BK; Lee A; Park S
Cancer Immunol Immunother; 2022 Apr; 71(4):967-978. PubMed ID: 34988585
[TBL] [Abstract][Full Text] [Related]
9. A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.
Dey N; Aske J; Lin X; Sun Y; Leyland-Jones B; Friedman L; De P
Am J Cancer Res; 2021; 11(6):2867-2892. PubMed ID: 34249433
[TBL] [Abstract][Full Text] [Related]
10. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
11. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.
Wang L; Yu X; Wang C; Pan S; Liang B; Zhang Y; Chong X; Meng Y; Dong J; Zhao Y; Yang Y; Wang H; Gao J; Wei H; Zhao J; Wang H; Hu C; Xiao W; Li B
Oncotarget; 2017 Aug; 8(32):52877-52888. PubMed ID: 28881779
[TBL] [Abstract][Full Text] [Related]
12. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Wang X; Li JP; Yang Y; Ding J; Meng LH
Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Young CD; Arteaga CL; Cook RS
Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
16. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
[TBL] [Abstract][Full Text] [Related]
17. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.
Mortenson ED; Park S; Jiang Z; Wang S; Fu YX
Clin Cancer Res; 2013 Mar; 19(6):1476-86. PubMed ID: 23363817
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
19. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations.
Chung WP; Huang WL; Lee CH; Hsu HP; Huang WL; Liu YY; Su WC
Am J Cancer Res; 2022; 12(7):3067-3082. PubMed ID: 35968355
[TBL] [Abstract][Full Text] [Related]
20. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
